Hardware, Equipment & Parts
Compare Stocks
5 / 10Stock Comparison
NOVT vs CGNX vs MKSI vs VIAV vs IPGP
Revenue, margins, valuation, and 5-year total return — side by side.
Hardware, Equipment & Parts
Hardware, Equipment & Parts
Communication Equipment
Semiconductors
NOVT vs CGNX vs MKSI vs VIAV vs IPGP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Communication Equipment | Semiconductors |
| Market Cap | $4.86B | $11.01B | $20.25B | $11.81B | $4.31B |
| Revenue (TTM) | $981M | $1.05B | $4.07B | $1.37B | $1.04B |
| Net Income (TTM) | $54M | $143M | $327M | $-55M | $29M |
| Gross Margin | 44.4% | 68.0% | 45.2% | 55.7% | 37.6% |
| Operating Margin | 11.9% | 18.8% | 14.8% | 8.2% | 0.3% |
| Forward P/E | 38.2x | 53.0x | 30.4x | 55.2x | 62.6x |
| Total Debt | $342M | $77M | $4.69B | $692M | $0.00 |
| Cash & Equiv. | $381M | $263M | $675M | $424M | $404M |
NOVT vs CGNX vs MKSI vs VIAV vs IPGP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Novanta Inc. (NOVT) | 100 | 132.7 | +32.7% |
| Cognex Corporation (CGNX) | 100 | 116.2 | +16.2% |
| MKS Inc. (MKSI) | 100 | 284.8 | +184.8% |
| Viavi Solutions Inc. (VIAV) | 100 | 440.5 | +340.5% |
| IPG Photonics Corpo… (IPGP) | 100 | 65.4 | -34.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NOVT vs CGNX vs MKSI vs VIAV vs IPGP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NOVT is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 8.5% 10Y total return vs MKSI's 7.5%
- PEG 11.61 vs VIAV's 12.09
CGNX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 4 yrs, beta 1.50, yield 0.5%
- Lower volatility, beta 1.50, Low D/E 5.1%, current ratio 3.80x
- Beta 1.50, yield 0.5%, current ratio 3.80x
- 13.6% margin vs VIAV's -4.0%
MKSI is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 9.6%, EPS growth 55.5%, 3Y rev CAGR 3.5%
- 9.6% revenue growth vs IPGP's 2.7%
- Lower P/E (30.4x vs 62.6x)
VIAV ranks third and is worth considering specifically for momentum.
- +466.6% vs NOVT's +14.6%
Among these 5 stocks, IPGP doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.6% revenue growth vs IPGP's 2.7% | |
| Value | Lower P/E (30.4x vs 62.6x) | |
| Quality / Margins | 13.6% margin vs VIAV's -4.0% | |
| Stability / Safety | Beta 1.50 vs MKSI's 2.64, lower leverage | |
| Dividends | 0.5% yield, 4-year raise streak, vs MKSI's 0.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +466.6% vs NOVT's +14.6% | |
| Efficiency (ROA) | 7.1% ROA vs VIAV's -2.3%, ROIC 9.0% vs 5.5% |
NOVT vs CGNX vs MKSI vs VIAV vs IPGP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NOVT vs CGNX vs MKSI vs VIAV vs IPGP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CGNX leads in 3 of 6 categories
MKSI leads 1 • VIAV leads 1 • NOVT leads 0 • IPGP leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CGNX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MKSI is the larger business by revenue, generating $4.1B annually — 4.2x NOVT's $981M. CGNX is the more profitable business, keeping 13.6% of every revenue dollar as net income compared to VIAV's -4.0%. On growth, VIAV holds the edge at +42.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $981M | $1.0B | $4.1B | $1.4B | $1.0B |
| EBITDAEarnings before interest/tax | $179M | $219M | $945M | $207M | $55M |
| Net IncomeAfter-tax profit | $54M | $143M | $327M | -$55M | $29M |
| Free Cash FlowCash after capex | $48M | $241M | $401M | $46M | $8M |
| Gross MarginGross profit ÷ Revenue | +44.4% | +68.0% | +45.2% | +55.7% | +37.6% |
| Operating MarginEBIT ÷ Revenue | +11.9% | +18.8% | +14.8% | +8.2% | +0.3% |
| Net MarginNet income ÷ Revenue | +5.5% | +13.6% | +8.0% | -4.0% | +2.8% |
| FCF MarginFCF ÷ Revenue | +4.9% | +23.0% | +9.8% | +3.3% | +0.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.5% | +24.3% | +15.2% | +42.8% | +16.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +121.4% | +53.2% | -70.2% | -54.4% |
Valuation Metrics
MKSI leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 68.8x trailing earnings, MKSI trades at a 80% valuation discount to VIAV's 340.3x P/E. Adjusting for growth (PEG ratio), NOVT offers better value at 28.13x vs VIAV's 74.57x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.9B | $11.0B | $20.2B | $11.8B | $4.3B |
| Enterprise ValueMkt cap + debt − cash | $4.8B | $10.8B | $24.3B | $12.1B | $3.9B |
| Trailing P/EPrice ÷ TTM EPS | 92.71x | 96.92x | 68.83x | 340.33x | 139.22x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.25x | 53.05x | 30.36x | 55.18x | 62.62x |
| PEG RatioP/E ÷ EPS growth rate | 28.13x | — | — | 74.57x | — |
| EV / EBITDAEnterprise value multiple | 27.00x | 55.96x | 26.70x | 90.43x | 48.90x |
| Price / SalesMarket cap ÷ Revenue | 4.96x | 11.07x | 5.15x | 10.89x | 4.30x |
| Price / BookPrice ÷ Book value/share | 3.81x | 7.48x | 7.49x | 14.77x | 2.04x |
| Price / FCFMarket cap ÷ FCF | 100.38x | 46.49x | 40.74x | 190.52x | — |
Profitability & Efficiency
CGNX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MKSI delivers a 12.2% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-7 for VIAV. CGNX carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), CGNX scores 7/9 vs VIAV's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.1% | +9.6% | +12.2% | -6.9% | +1.4% |
| ROA (TTM)Return on assets | +3.0% | +7.1% | +3.7% | -2.3% | +1.2% |
| ROICReturn on invested capital | +7.4% | +9.0% | +6.5% | +5.5% | +0.6% |
| ROCEReturn on capital employed | +8.3% | +8.9% | +7.2% | +4.9% | +0.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.26x | 0.05x | 1.73x | 0.89x | — |
| Net DebtTotal debt minus cash | -$39M | -$186M | $4.0B | $269M | -$404M |
| Cash & Equiv.Liquid assets | $381M | $263M | $675M | $424M | $404M |
| Total DebtShort + long-term debt | $342M | $77M | $4.7B | $692M | $0 |
| Interest CoverageEBIT ÷ Interest expense | 4.89x | — | 2.84x | 2.70x | — |
Total Returns (Dividends Reinvested)
VIAV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VIAV five years ago would be worth $31,204 today (with dividends reinvested), compared to $5,151 for IPGP. Over the past 12 months, VIAV leads with a +466.6% total return vs NOVT's +14.6%. The 3-year compound annual growth rate (CAGR) favors VIAV at 77.7% vs NOVT's -5.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.6% | +78.7% | +78.8% | +181.3% | +35.8% |
| 1-Year ReturnPast 12 months | +14.6% | +133.1% | +306.1% | +466.6% | +75.6% |
| 3-Year ReturnCumulative with dividends | -15.2% | +34.7% | +266.0% | +461.0% | -12.7% |
| 5-Year ReturnCumulative with dividends | +5.7% | -13.2% | +66.5% | +212.0% | -48.5% |
| 10-Year ReturnCumulative with dividends | +853.7% | +249.6% | +750.6% | +715.5% | +20.2% |
| CAGR (3Y)Annualised 3-year return | -5.3% | +10.4% | +54.1% | +77.7% | -4.4% |
Risk & Volatility
Evenly matched — CGNX and MKSI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CGNX is the less volatile stock with a 1.50 beta — it tends to amplify market swings less than MKSI's 2.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MKSI currently trades 92.0% from its 52-week high vs IPGP's 65.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 1.50x | 2.64x | 1.54x | 1.80x |
| 52-Week HighHighest price in past year | $149.95 | $71.90 | $326.83 | $60.43 | $155.82 |
| 52-Week LowLowest price in past year | $98.27 | $27.82 | $71.49 | $8.87 | $53.98 |
| % of 52W HighCurrent price vs 52-week peak | +90.9% | +91.7% | +92.0% | +84.5% | +65.2% |
| RSI (14)Momentum oscillator 0–100 | 62.6 | 76.3 | 65.3 | 66.7 | 39.7 |
| Avg Volume (50D)Average daily shares traded | 375K | 2.0M | 1.2M | 6.3M | 510K |
Analyst Outlook
CGNX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NOVT as "Buy", CGNX as "Hold", MKSI as "Buy", VIAV as "Buy", IPGP as "Buy". Consensus price targets imply 49.2% upside for IPGP (target: $152) vs -36.8% for VIAV (target: $32). For income investors, CGNX offers the higher dividend yield at 0.49% vs MKSI's 0.29%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $150.00 | $60.22 | $272.86 | $32.25 | $151.67 |
| # AnalystsCovering analysts | 3 | 31 | 29 | 19 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | +0.3% | — | — |
| Dividend StreakConsecutive years of raises | — | 4 | 0 | 1 | 1 |
| Dividend / ShareAnnual DPS | — | $0.32 | $0.87 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.8% | +1.4% | +0.2% | +0.1% | +1.3% |
CGNX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MKSI leads in 1 (Valuation Metrics). 1 tied.
NOVT vs CGNX vs MKSI vs VIAV vs IPGP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NOVT or CGNX or MKSI or VIAV or IPGP a better buy right now?
For growth investors, MKS Inc.
(MKSI) is the stronger pick with 9. 6% revenue growth year-over-year, versus 2. 7% for IPG Photonics Corporation (IPGP). MKS Inc. (MKSI) offers the better valuation at 68. 8x trailing P/E (30. 4x forward), making it the more compelling value choice. Analysts rate Novanta Inc. (NOVT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NOVT or CGNX or MKSI or VIAV or IPGP?
On trailing P/E, MKS Inc.
(MKSI) is the cheapest at 68. 8x versus Viavi Solutions Inc. at 340. 3x. On forward P/E, MKS Inc. is actually cheaper at 30. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novanta Inc. wins at 11. 61x versus Viavi Solutions Inc. 's 12. 09x.
03Which is the better long-term investment — NOVT or CGNX or MKSI or VIAV or IPGP?
Over the past 5 years, Viavi Solutions Inc.
(VIAV) delivered a total return of +212. 0%, compared to -48. 5% for IPG Photonics Corporation (IPGP). Over 10 years, the gap is even starker: NOVT returned +853. 7% versus IPGP's +20. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NOVT or CGNX or MKSI or VIAV or IPGP?
By beta (market sensitivity over 5 years), Cognex Corporation (CGNX) is the lower-risk stock at 1.
50β versus MKS Inc. 's 2. 64β — meaning MKSI is approximately 75% more volatile than CGNX relative to the S&P 500. On balance sheet safety, Cognex Corporation (CGNX) carries a lower debt/equity ratio of 5% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NOVT or CGNX or MKSI or VIAV or IPGP?
By revenue growth (latest reported year), MKS Inc.
(MKSI) is pulling ahead at 9. 6% versus 2. 7% for IPG Photonics Corporation (IPGP). On earnings-per-share growth, the picture is similar: Viavi Solutions Inc. grew EPS 225. 0% year-over-year, compared to -16. 9% for Novanta Inc.. Over a 3-year CAGR, NOVT leads at 4. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NOVT or CGNX or MKSI or VIAV or IPGP?
Cognex Corporation (CGNX) is the more profitable company, earning 11.
5% net margin versus 3. 1% for IPG Photonics Corporation — meaning it keeps 11. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CGNX leads at 16. 3% versus 1. 3% for IPGP. At the gross margin level — before operating expenses — CGNX leads at 66. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NOVT or CGNX or MKSI or VIAV or IPGP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Novanta Inc. (NOVT) is the more undervalued stock at a PEG of 11. 61x versus Viavi Solutions Inc. 's 12. 09x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, MKS Inc. (MKSI) trades at 30. 4x forward P/E versus 62. 6x for IPG Photonics Corporation — 32. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IPGP: 49. 2% to $151. 67.
08Which pays a better dividend — NOVT or CGNX or MKSI or VIAV or IPGP?
In this comparison, CGNX (0.
5% yield), MKSI (0. 3% yield) pay a dividend. NOVT, VIAV, IPGP do not pay a meaningful dividend and should not be held primarily for income.
09Is NOVT or CGNX or MKSI or VIAV or IPGP better for a retirement portfolio?
For long-horizon retirement investors, Viavi Solutions Inc.
(VIAV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+715. 5% 10Y return). IPG Photonics Corporation (IPGP) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VIAV: +715. 5%, IPGP: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NOVT and CGNX and MKSI and VIAV and IPGP?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.